NCT05732662View on ClinicalTrials.gov

SBRT Combined With AK104 to Treatment Relapsed or Metastatic ESCC

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

25

Participants

Timeline

Start Date

April 30, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions

Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Interventions

RADIATION

SBRT

24-50Gy/8-12.5Gy/3-4f

DRUG

Cadonilimab

10 mg/kg,q3w

All Listed Sponsors

lead

The First People's Hospital of Changzhou

OTHER